Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi ...

Heart failure (HF) is a complex and rapidly increasing syndrome, with an estimated prevalence of 1.1–5.5 per cent, accounting ...

The company expects the European Commission (EC) to make a final decision on the marketing authorization in June 2025.

Alnylam Pharmaceuticals said its RNAi therapeutic vutrisiran received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Intellia Therapeutics, Inc.’s NTLA share price has surged by 5.05%, which has investors questioning if this is right time to ...

SS&C Technologies Holdings, Inc. today announced the return of its flagship EMEA event, SS&C Deliver, taking place May 13-14, 2025, at the Fairmont Windsor Park, just outside London. With the theme ...

Sensydia, a medical technology company pioneering non-invasive cardiac assessment, today announced that the first patient has been enrolled in its multi-center pivotal study to evaluate the accuracy ...

The Board of Directors of Hexaware Technologies Limited, at its meeting held today have approved the financial results of the ...

The Board of Directors of Shiva Cement Limited, at its meeting held today have approved the financial results of the company ...